173 related articles for article (PubMed ID: 26549181)
1. Targets to treat androgen excess in polycystic ovary syndrome.
Luque-Ramírez M; Escobar-Morreale HF
Expert Opin Ther Targets; 2015; 19(11):1545-60. PubMed ID: 26549181
[TBL] [Abstract][Full Text] [Related]
2. Androgens and polycystic ovary syndrome.
Nisenblat V; Norman RJ
Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
[TBL] [Abstract][Full Text] [Related]
3. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
[TBL] [Abstract][Full Text] [Related]
4. Androgen circle of polycystic ovary syndrome.
Homburg R
Hum Reprod; 2009 Jul; 24(7):1548-55. PubMed ID: 19279033
[TBL] [Abstract][Full Text] [Related]
5. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
Abbott DH; Barnett DK; Bruns CM; Dumesic DA
Hum Reprod Update; 2005; 11(4):357-74. PubMed ID: 15941725
[TBL] [Abstract][Full Text] [Related]
6. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
Xita N; Tsatsoulis A
J Clin Endocrinol Metab; 2006 May; 91(5):1660-6. PubMed ID: 16522691
[TBL] [Abstract][Full Text] [Related]
7. Androgens in polycystic ovary syndrome: the role of exercise and diet.
Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
[TBL] [Abstract][Full Text] [Related]
8. Use of antiandrogens as therapy for women with polycystic ovary syndrome.
Moghetti P
Fertil Steril; 2006 Jul; 86 Suppl 1():S30-1. PubMed ID: 16798285
[TBL] [Abstract][Full Text] [Related]
9. Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs.
Yanes Cardozo LL; Romero DG
FASEB J; 2021 Nov; 35(11):e21945. PubMed ID: 34606638
[TBL] [Abstract][Full Text] [Related]
10. Dermatology of androgen-related disorders.
Essah PA; Wickham EP; Nunley JR; Nestler JE
Clin Dermatol; 2006; 24(4):289-98. PubMed ID: 16828411
[TBL] [Abstract][Full Text] [Related]
11. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
[TBL] [Abstract][Full Text] [Related]
12. Treatment options of polycystic ovary syndrome in adolescence.
Zapanti E; Kiapekou E; Loutradis D
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():208-13. PubMed ID: 16641862
[TBL] [Abstract][Full Text] [Related]
13. [Advance in treatment of polycystic ovary syndrome].
Krysiak R; Okopień B; Herman ZS
Pol Merkur Lekarski; 2005 Dec; 19(114):848-54. PubMed ID: 16521439
[TBL] [Abstract][Full Text] [Related]
14. [Polycystic ovary syndrome].
Campodónico I; Cheviakoff S; Devoto L; Glavic A; Porcile A; Reid I
Rev Chil Obstet Ginecol; 1983; 48(1):16-26. PubMed ID: 6681188
[No Abstract] [Full Text] [Related]
15. Pharmacological options for treatment of hyperandrogenic disorders.
Reismann P; Likó I; Igaz P; Patócs A; Rácz K
Mini Rev Med Chem; 2009 Aug; 9(9):1113-26. PubMed ID: 19689407
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome: chemical pharmacotherapy.
Rocca ML; Venturella R; Mocciaro R; Di Cello A; Sacchinelli A; Russo V; Trapasso S; Zullo F; Morelli M
Expert Opin Pharmacother; 2015 Jun; 16(9):1369-93. PubMed ID: 26001184
[TBL] [Abstract][Full Text] [Related]
17. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
Domecq JP; Prutsky G; Mullan RJ; Sundaresh V; Wang AT; Erwin PJ; Welt C; Ehrmann D; Montori VM; Murad MH
J Clin Endocrinol Metab; 2013 Dec; 98(12):4646-54. PubMed ID: 24092830
[TBL] [Abstract][Full Text] [Related]
18. [Hyperandrogenism: clinical aspects, investigation and treatment].
Beckers A; Parotte MC; Gaspard U; Khalife A
Rev Med Liege; 1999 Apr; 54(4):274-82. PubMed ID: 10389470
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
Blank SK; McCartney CR; Helm KD; Marshall JC
Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
[TBL] [Abstract][Full Text] [Related]
20. A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.
Luque-Ramírez M; Ortiz-Flores AE; Nattero-Chávez L; Escobar-Morreale HF
Expert Opin Drug Saf; 2020 Dec; 19(12):1559-1576. PubMed ID: 33070640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
